

Hon Mrs Volda Lawrence  
Minister of Public Health  
Ministry of Public Health  
Brickdam, Stabroek  
Georgetown  
Republic of Guyana

20 March 2017

***Decision Letter: Request for new vaccine support – Human papillomavirus (HPV)***

Your Excellency,

I am writing in relation to Guyana's proposal for Human Papillomavirus Vaccine Support submitted to the Gavi Secretariat in September 2016, and the response to the clarifications requested by the Independent Review Committee (IRC), which Guyana submitted on 08 January 2017.

The clarifications were found to be satisfactory and based on the recommendations made by the IRC, Gavi, the Vaccine Alliance has **approved** the Human Papillomavirus Vaccine proposal subject to a number of recommendations as specified in the appendices to this letter.

Please do not hesitate to contact my colleague Mr L. Homero Hernandez, Senior Country Manager for Guyana, at [hhernandez@gavi.org](mailto:hhernandez@gavi.org) if you have any questions or concerns.

Sincerely yours,



Hind Khatib-Othman  
Managing Director, Country Programmes

Appendix A: Guyana Support for Human Papillomavirus Vaccine (HPV)  
Appendix B: Guyana Support for Immunisation supplies

Cc: Minister of Finance  
Director of Planning, Ministry of Health  
EPI Manager, Ministry of Health  
WHO Country Representative  
WHO AMRO/PAHO  
WHO HQ  
UNICEF Country Representative  
UNICEF Regional Office  
UNICEF Programme Division

**Decision Letter  
Guyana - Support for Human Papillomavirus Vaccine (HPV)**

**This Decision Letter sets out the Programme Terms of a Programme.**

|  |             |                          |
|--|-------------|--------------------------|
| <b>1. Country:</b> Guyana  |             |                          |
| <b>2. Vaccines grant number:</b> 17-GUY-19b-X / 17-GUY-08f-Y   |             |                          |
| <b>3. Date of Decision Letter:</b> 20/03/2017  |             |                          |
| <b>4. Date of the partnership framework agreement:</b> 05/02/2015  |             |                          |
| <b>5. Programme title:</b> New Vaccine Support (NVS), HPV Routine  |             |                          |
| <b>6. Vaccine type:</b> Human Papillomavirus Vaccine   |             |                          |
| <b>7. Requested product presentation and formulation of vaccine:</b> HPV Quadrivalent, 1 dose per vial, LIQUID                             |             |                          |
| <b>8. Programme duration<sup>1</sup>:</b> 2017   |             |                          |
| <b>9. Programme Budget (indicative):</b> (subject to the terms of the Partnership Framework Agreement, if applicable)                      |             |                          |
|  | <b>2017</b> | <b>Total<sup>2</sup></b> |
| <b>Programme Budget (US\$)</b>   | 49,500      | 49,500                   |
| <b>10. Vaccine introduction grant:</b> US\$100,000   |             |                          |
| <b>11. Indicative Annual Amounts:</b> (subject to the terms of the Partnership Framework Agreement, if applicable) <sup>3</sup>            |             |                          |
| <b>Type of supplies to be purchased with Gavi funds in each year</b>   |             | <b>2017</b>              |
| Number of HPV vaccines doses   |             | 10,800                   |
| <b>Annual Amounts (US\$)</b>   |             | <b>49,500</b>            |
| <b>12. Procurement agency:</b> PAHO. The Country shall release its co-financing payments each year to PAHO.                                |             |                          |
| <b>13. Self-procurement:</b> Not applicable  |             |                          |
| <b>14. Co-financing obligations:</b> Reference code: 17-GUY-19b-X-C  |             |                          |
| The following table summarises the co-financing payment and quantity of supply that will be recurred with such funds in the relevant year. |             |                          |
| <b>Type of supplies to be purchased with Country funds in each year</b>  |             | <b>2017</b>              |
| Number of vaccines doses   |             | 10,800                   |
| Value of vaccine doses (US\$)  |             | 48,263                   |
| AD syringes  |             | 11,400                   |
| Safety boxes   |             | 125                      |
| <b>Total co-financing payments (US\$) (including freight)</b>  |             | <b>50,000</b>            |
| <b>15. Operational support for campaigns:</b> Not applicable.  |             |                          |
| <b>16. Additional reporting requirements:</b>  |             |                          |
| <b>Reports other information</b>   |             | <b>Due dates</b>         |

<sup>1</sup> This is the entire duration of the Programme.

<sup>2</sup> This is the total amount endorsed by Gavi for the entire duration of the Programme.

<sup>3</sup> This is the amount that Gavi has approved.

|   |                               |
|---|-------------------------------|
| To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received. | 15 May                        |
| In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.   | To be agreed with Secretariat |
| <b>17. Financial clarifications:</b> Not applicable   |                               |
| <b>18. Other conditions:</b> Not applicable   |                               |

**On behalf of Gavi**

Signed by,



Hind Khatib-Othman  
Managing Director, Country Programmes  
20 March 2017

**Decision Letter**  
**Guyana Support for Injection safety devices**

**This Decision Letter sets out the Programme Terms of a Programme.**

|  |                   |                           |
|--|-------------------|---------------------------|
| <b>1. Country:</b> Guyana  |                   |                           |
| <b>2. Grant number:</b> 17-GUY-32a-X   |                   |                           |
| <b>3. Date of Decision Letter:</b> 20/03/2017  |                   |                           |
| <b>4. Date of the Partnership Framework Agreement:</b> 05/02/2015  |                   |                           |
| <b>5. Programme title:</b> Injection safety devices <sup>4</sup>   |                   |                           |
| <b>6. Programme duration</b> <sup>5</sup> : 2017   |                   |                           |
| <b>7. Programme Budget (indicative):</b> (subject to the terms of the partnership framework agreement, if applicable)          |                   |                           |
|  | <b>2017</b>       | <b>Total</b> <sup>6</sup> |
| <b>Programme Budget (US\$)</b>   | 2,000             | <b>2,000</b>              |
| <b>8. Indicative Annual Amounts:</b> (subject to the terms of the Partnership Framework Agreement, if applicable) <sup>7</sup> |                   |                           |
| <b>TOTAL injection safety devices to be purchased with Gavi funds in each year</b>   | <b>2017</b>       |                           |
| Number of AD syringes  | 28,600            |                           |
| Number of safety boxes   | 325               |                           |
| <b>Annual Amounts for injection safety devices for all Gavi vaccines (US\$)</b>  | <b>US\$ 2,000</b> |                           |
| <b>Injection safety devices to be purchased with Gavi funds in each year, by type of support</b>                               |                   |                           |
| <b>New Vaccine Support (NVS), Inactivated Polio Vaccine, 5 dose(s) per vial, LIQUID, Routine</b>                               | <b>2017</b>       |                           |
| Number of AD syringes  | 17,200            |                           |
| Number of safety boxes   | 200               |                           |
| <b>Annual Amounts for injection safety devices for Vaccine (US\$)</b>  | <b>US\$ 1,000</b> |                           |
| <b>New Vaccine Support (NVS), HPV Quadrivalent, 1 dose(s) per vial, LIQUID</b>   | <b>2017</b>       |                           |
| Number of AD syringes  | 11,400            |                           |
| Number of safety boxes   | 125               |                           |
| <b>Annual Amounts for injection safety devices for Vaccine (US\$)</b>  | <b>US\$ 1,000</b> |                           |
| <b>9. Procurement agency:</b> PAHO.  |                   |                           |
| <b>10. Self-procurement:</b> Not applicable  |                   |                           |
| <b>11. Co-financing obligations:</b> Co-financing requirements are listed in the relevant vaccine Decision Letter.             |                   |                           |

**On behalf of Gavi**

Signed by,



Hind Khatib-Othman  
 Managing Director, Country Programmes  
 20 March 2017

<sup>4</sup> This does not include vaccines.

<sup>5</sup> This is the entire duration of the Programme.

<sup>6</sup> This is the total amount endorsed by Gavi for the entire duration of the Programme.

<sup>7</sup> This is the amount that Gavi has approved.